health 49

Principal results were published in the  New England Journal of Medicine  of a global Phase 3 clinical trial in patients with type 1 diabetes treated with sotagliflozin. Sotagliflozin is an investigational new oral drug for patients with type 1 diabetes that has shown promise in improving glucose control without any increase in severe hypoglycemia or diabetic ketoacidosis compared to insulin alone. Among 1,402 trial participants given the drug, sotagliflozin showed clinically meaningful and statistically significant effects on glucose control. Concentrations of hemoglobin A1C, a measure of plasma glucose, were improved. Patients experienced a lower rate of confirmed severe hypoglycemia than observed in patients on placebo and also had weight loss. According to lead investigator Satish Garg, MD, professor of medicine and pediatrics at the Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus, no oral medication has ever been approved for...

"Ecstasy or 'Molly' users in the U.S. are at very high risk for using drugs containing adulterants such as 'bath salts' and methamphetamine," said Dr. Joseph Palamar, PhD, MPH, of the New York University Rory Meyers College of Nursing Center for Drug Use and HIV Research (NYU CDUHR). "More information is critically needed on the extent of unknown or unintentional use of these potentially harmful substances." Dr. Palamar's study, "Hair Testing to Assess Both Known and Unknown Use of Drugs Amongst Ecstasy Users in the Electronic Music Dance Scene," published in the  International Journal of Drug Policy , surveyed self-reported past-year ecstasy/MDMA/Molly users attending EDM parties in New York City (NYC), using hair testing to determine the types of drugs participants had consumed. "Hair testing for new psychoactive substances is an important new addition to biological testing. While blood, urine, and saliva are often adequate...